BDBM250027 US10005782, Compound 149::US9447106, 149::US9556188, Compound 149

SMILES NC(=O)c1c2NCCC(c3ccccc3NC(=O)C=C)n2nc1-c1ccc(OC(F)(F)F)cc1

InChI Key InChIKey=CXOPEXZCBUQYKF-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 250027   

TargetTyrosine-protein kinase BTK(Human)
Beigene

US Patent
LigandPNGBDBM250027(US9447106, 149 | US9556188, Compound 149 | US10005...)
Affinity DataIC50: 4.20nMT: 2°CAssay Description:Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/18/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Beigene

US Patent
LigandPNGBDBM250027(US9447106, 149 | US9556188, Compound 149 | US10005...)
Affinity DataIC50: 4.20nMT: 2°CAssay Description:Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/12/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Beigene

US Patent
LigandPNGBDBM250027(US9447106, 149 | US9556188, Compound 149 | US10005...)
Affinity DataIC50: 4.20nMAssay Description:Compounds disclosed herein were tested for inhibition of Btk kinase activity in an assay based on time-resolved fluorescence resonance energy transfe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/18/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Beigene

US Patent
LigandPNGBDBM250027(US9447106, 149 | US9556188, Compound 149 | US10005...)
Affinity DataIC50: 4.20nMAssay Description:Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr fol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
TBA

Curated by ChEMBL
LigandPNGBDBM250027(US9447106, 149 | US9556188, Compound 149 | US10005...)
Affinity DataIC50: 0.460nMAssay Description:Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
TBA

Curated by ChEMBL
LigandPNGBDBM250027(US9447106, 149 | US9556188, Compound 149 | US10005...)
Affinity DataIC50: 0.460nMAssay Description:Inhibition of EGFR (unknown origin) preincubated for 1 hr followed by Biotin-AVLESEEELYSSARQ-NH2 substrate addition in presence of ATP and measured a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Beigene

US Patent
LigandPNGBDBM250027(US9447106, 149 | US9556188, Compound 149 | US10005...)
Affinity DataIC50: 4.20nMAssay Description:Inhibition of N-terminal His-tagged recombinant human BTK (393 to 659 residues) expressed in baculovirus infected Sf9 cells preincubated for 1 hr fol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed